[1]张 申,张 磊,仲斌演,等.“TACE抵抗/失败”——需要全面认识[J].介入放射学杂志,2020,29(08):743-747.
　ZHANG Shen,ZHANG Lei,ZHONG Binyan,et al.Comprehensive understanding of the concept and connotation of “TACE- failure/refractoriness”[J].journal interventional radiology,2020,29(08):743-747.
点击复制

“TACE抵抗/失败”——需要全面认识()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年08
页码:
743-747
栏目:
专论
出版日期:
2020-08-25

文章信息/Info

Title:
Comprehensive understanding of the concept and connotation of “TACE- failure/refractoriness”
作者:
张 申;  张 磊;  仲斌演;  王万胜;  倪才方
Author(s):
ZHANG Shen;  ZHANG Lei;  ZHONG Binyan;  WANG Wansheng;  NI Caifang.
Department of Interventional Radiology， First Affiliated Hospital of Soochow University， Suzhou， Jiangsu Province 215006， China
关键词:
【关键词】 肝细胞癌;  经导管动脉化疗栓塞术;  失败;  抵抗
文献标志码:
A
摘要:
【摘要】 经导管动脉化疗栓塞术（TACE）是公认的中期肝细胞癌（HCC）患者标准治疗方法。然而，由于TACE本身固有的局限性和患者显著的异质性，部分患者存在多次TACE术后肿瘤控制仍然不佳的情况。基于此，近年来“TACE抵抗/失败”的概念备受关注，但有关“TACE抵抗/失败”的定义、内涵存在诸多模糊，甚至矛盾之处。该文就“TACE抵抗/失败”概念、内涵进行解读和分析，试图予以厘清，以更好地对其进行全面与深入的研究，从而进一步提高肝癌治疗效果。

参考文献/References:


［1］ European Association for the Study of the Liver， European Association for the Study of the Liver. EASL clinical practice guidelines： management of hepatocellular carcinoma［J］. J Hepatol， 2018， 69：182- 236.
［2］ Kokudo N， Takemura N， Hasegawa K， et al. Clinical practice guidelines for hepatocellular carcinoma： The Japan Society of Hepatology 2017（4th JSH‐HCC guidelines） 2019 update［J］. Hepatol Res， 2019， 49：1109- 1113.
［3］ 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范（2019年版）［J］. 中国临床医学， 2020， 27：140- 160.
［4］ 余晨曦，滕皋军. 经导管动脉化疗栓塞术抵抗研究进展［J］. 介入放射学杂志， 2017， 26：1063- 1067.
［5］ Kajihara J， Tomimaru Y， Eguchi H， et al. The clinical impact of transcatheter arterial chemoembolization（TACE）- induced c- Met upregulation on TACE refractoriness in hepatocellular carcinoma［J］. Dig Dis Sci， 2016， 61：1572- 1581.
［6］ Marelli L， Stigliano R， Triantos C， et al. Transarterial therapy for hepatocellular carcinoma： which technique is more effective? A systematic review of cohort and randomized studies［J］. Cardiovasc Intervent Radiol， 2007， 30：6- 25.
［7］ Raoul JL， Gilabert M， Piana G. How to define transarterial chemo-embolization failure or refractoriness： a European perspective［J］. Liver Cancer， 2014， 3：119- 124.
［8］ Kim HY， Park J， Joo J， et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma［J］. J Gastroenterol Hepatol， 2012， 27：1051- 1056.
［9］ Kudo M， Matsui O， Izumi N， et al. Transarterial chemoembo-lization failure/refractoriness： JSH- LCSGJ criteria 2014 update［J］. Oncology， 2014， 87（Suppl 1）：22- 31.
［10］ Arizumi T， Ueshima K， Minami T， et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization（TACE） refractory and intermediate- stage hepatocellular car-cinoma［J］. Liver Cancer， 2015， 4：253- 262.
［11］ Arizumi T， Minami T， Chishina H， et al. Time to transcatheter arterial chemoembolization refractoriness in patients with hepa-tocellular carcinoma in Kinki criteria stages B1 and B2［J］. Dig Dis， 2017， 35：589- 597.
［12］ 中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗（TACE）临床实践指南［J］. 中华医学杂志， 2018， 98：3811- 3819.
［13］ Kudo M， Ueshima K， Ikeda M， et al. Randomised， multicentre prospective trial of transarterial chemoembolisation（TACE） plus sorafenib as compared with TACE alone in patients with hepato-cellular carcinoma： TACTICS trial［J］. Gut， 2020， 69：1492-1501.

［14］ Pleguezuelo M， Marelli L， Misseri M， et al. TACE versus TAE as therapy for hepatocellular carcinoma［J］. Expert Rev Anticancer Ther， 2014， 8：1623- 1641.
［15］ Maeda N， Osuga K， Higashihara H， et al. Transarterial chemo-embolization with cisplatin as second- line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin- lipiodol emulsion［J］. Cardiovasc Intervent Radiol， 2012， 35：82- 89.
［16］ Seki A， Hori S. Switching the loaded agent from epirubicin to cisplatin： salvage transcatheter arterial chemoembolization with drug- eluting microspheres for unresectable hepatocellular carcinoma［J］. Cardiovasc Intervent Radiol， 2012， 35：555- 562.
［17］ Lohitesh K， Chowdhury R， Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma： an insight［J］. Cancer Cell Int， 2018， 18：44.
［18］ Raoul JL， Forner A， Bolondi L， et al. Updated use of TACE for hepatocellular carcinoma treatment： how and when to use it based on clinical evidence［J］. Cancer Treat Rev， 2019， 72：28- 36.
［19］ Meyer T， Kirkwood A， Roughton M， et al. A randomised phase II/III trial of 3- weekly cisplatin- based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma［J］. Br J Cancer， 2013， 108：1252- 1259.
［20］ Miyayama S， Matsui O， Yamashiro M， et al. Ultraselective transcatheter arterial chemoembolization with a 2- f tip microca-theter for small hepatocellular carcinomas： relationship between local tumor recurrence and visualization of the portal vein with iodized Oil［J］. J Vascu Interv Radiol， 2007， 18：365- 376.
［21］ Georgiades C， Geschwind JF， Harrison N， et al. Lack of response after initial chemoembolization for hepatocellular carcinoma： does it predict failure of subsequent treatment?［J］. Radiology， 2012， 265：115- 123.
［22］ Zen C， Zen Y， Mitry RR， et al. Mixed phenotype hepatocellular carcinoma after trans- arterial chemoembolization（TACE） and liver transplantation［J］. Liver Transpl， 2011， 17：943- 954.
［23］ Jain RK. Normalization of tumor vasculature： an emerging concept in antiangiogenic therapy［J］. Science， 2005， 307：58- 62.
［24］ Kudo M， Ueshima K， Kubo S， et al. Response evaluation criteria in cancer of the liver（RECICL）（2015 revised version）［J］. Hepatol Res， 2016， 46：3- 9.
［25］ Zhang Y， Li J， Cao L， et al. Circulating tumor cells in hepato-cellular carcinoma： detection techniques， clinical implications， and future perspectives［J］. Semin Oncol， 2012， 39：449- 460.
［26］ Shah SA， Greig PD， Gallinger S， et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes［J］. J Am Coll Surg， 2006， 202：275- 283.
［27］ Okusaka T， Okada S， Ueno H， et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinico- pathologic features［J］. Cancer， 2002， 95：1931- 1937.
［28］ Lauwers GY， Terris B， Balis UJ， et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas： a multi- institutional analysis of 425 patients with definition of a histologic prognostic index［J］. Am J Surg Pathol， 2002， 26：25- 34.
［29］ Rodriguez- Peralvarez M， Luong TV， Andreana L， et al. a systematic review of microvascular invasion in hepatocellular carcinoma： diagnostic and prognostic variability［J］. Ann Surg Oncol， 2013， 20：325- 339.
［30］ Kudo M， Han G， Finn RS， et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma： a randomized phase Ⅲ trial［J］. Hepatology， 2014， 60：1697- 1707.
［31］ Kudo M， Cheng AL， Park JW， et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma（ORIENTAL）： a randomised， double- blind， placebo- controlled， multicentre， phase 3 study［J］. Lancet Gastroenterol Hepatol， 2018， 3：37- 46.
［32］ Shi F， Wu M， Lian SS， et al. Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization：long- term outcomes［J］. Radiology， 2019， 293：707- 715.
［33］ Han K， Kim JH， Ko G， et al. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis： a comprehensive review［J］. World J Gastroenterol， 2016， 22：407- 416.
［34］ Cheng S， Chen M， Cai J， et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus（2018 edition）［J］. Liver Cancer， 2020， 9：28- 40.
［35］ Cheng AL， Kang YK， Chen ZD， et al. Efficacy and safety of sorafenib in patients in the Asia- Pacific region with advanced hepatocellular carcinoma： a phase Ⅲ randomised，double- blind，placebo- controlled trial［J］. Lancet Oncol， 2009， 10：25- 34.
［36］ Park JW， Chen M， Colombo M， et al. Global patterns of hepatocellular carcinoma management from diagnosis to death： the BRIDGE study［J］. Liver Int， 2015， 35：2155- 2166.
［37］ Xue TC， Xie XY， Zhang L， et al. Transarterial chemoembo-lization for hepatocellular carcinoma with portal vein tumor thrombus： a meta- analysis［J］. BMC Gastroenterol， 2013， 13：60.
［38］ Luo J， Guo RP， Lai ECH， et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis： a prospective comparative study［J］. Ann Surg Oncol，2011， 18：413- 420.
［39］ Pinter M， Hucke F， Graziadei I， et al. Advanced- stage hepatoc-ellular carcinoma： transarterial chemoembolization versus sorafenib［J］. Radiology， 2012， 263：590- 599.
［40］ Pan T， Li XS， Xie QK， et al. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus［J］. Clin Radiol， 2014， 69：e553- e561.
［41］ Zhu K， Chen J， Lai L， et al. Hepatocellular carcinoma with portal vein tumor thrombus： treatment with transarterial chemo-embolization combined with sorafenib：a retrospective controlled study［J］. Radiology， 2014， 272：284- 293.
［42］ Chung SM， Yoon CJ， Lee SS， et al. Treatment outcomes of transcatheter arterial chemoembolization for hepatocellular carcinoma that invades hepatic vein or inferior vena cava［J］. Cardiovasc Intervent Radiol， 2014， 37：1507- 1515.
［43］ Lau WY， Lai ECH. Loco- regional intervention for hepatocellular carcinoma［J］. J Intervent Med， 2019， 2：43- 46.
［44］ Wang S， Zheng Y， Liu J， et al. Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation［J］. J Investig Med， 2018， 66：1- 6.
［45］ Choi GH， Shim JH， Kim MJ， et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced- stage hepatocellular carcinoma：results of propensity score analyses［J］. Radiology， 2013， 269：603- 611.
［46］ Kim J， Sinn DH， Choi MS， et al. Hepatocellular carcinoma with extrahepatic metastasis： are there still candidates for transarterial chemoembolization as an initial treatment?［J］. PLoS One， 2019，14：e0213547.
［47］ Kang SH， Kim DY， Jeon SM， et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA- Ⅱ levels［J］. Eur J Gastroenterol Hepatol， 2012， 24：849- 856.
［48］ Park H， Park JY. Clinical significance of AFP and PIVKA- Ⅱ responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma［J］. Biomed Res Int， 2013， 2013： 310427.
［49］ Wang EX， Liu L， Xia DD， et al. Chemoembolization for hepatocellular carcinoma in patients with extrahepatic spread： prognostic determinants and appropriate candidates［J］. J Vasc Interv Radiol， 2017， 28：956- 962.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(08):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(08):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(08):206.
[4]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(08):621.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(08):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(08):974.
[7]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(08):78.
[8]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(08):636.
[9]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(08):520.
[10]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(08):769.
[11]王以浪,王亚非,张 亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
　WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(08):406.
[12]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114.
　YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(08):1114.
[13]刘璐璐,邵国良,庞佩佩.磁共振弥散加权和动态增强成像评价晚期肝癌TACE术疗效研究进展 [J].介入放射学杂志,2017,(08):756.
　LIU Lulu,SHAO Guoliang,PANG Peipei.Application of diffusion- weighted and dynamic contrast- enhanced MRI in evaluating the curative effect of TACE for advanced hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(08):756.
[14]中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗（TACE）临床实践指南[J].介入放射学杂志,2018,27(12):1117.
　Chinese College of Interventionalists,Chinese Medical Doctor Association.Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma[J].journal interventional radiology,2018,27(08):1117.
[15]刘 嵘,程永德,王小林,等.中国肝细胞癌TACE治疗的历史、现状和展望 ——纪念我国介入放射学奠基人林贵教授[J].介入放射学杂志,2022,31(08):743.
　LIU Rong,CHENG Yongde,WANG Xiaolin,et al.The history, status and future of transarterial chemoembolization of hepatocellular carcinoma in China: in memory of Professor Gui Lin, the founder of interventional radiology in China[J].journal interventional radiology,2022,31(08):743.
[16]夏子聪,赵 辉.改善经导管动脉化疗栓塞术疗效的临床及基础研究进展[J].介入放射学杂志,2023,32(07):705.
　XIA Zicong,ZHAO Hui..Advances in clinical and fundamental researches for improving the efficacy of transcatheter arterial chemoembolization[J].journal interventional radiology,2023,32(08):705.
[17]陆一峰,王 祁,何忠明.构建基于控制营养状况评分的列线图预测肝细胞癌TACE治疗患者预后[J].介入放射学杂志,2023,32(12):1190.
　LU Yifeng,WANG Qi,HE Zhongming..Construction of a nomogram based on controlling nutritional status score for predicting the prognosis of hepatocellular carcinoma patients after receiving TACE[J].journal interventional radiology,2023,32(08):1190.
[18]管清龙,陈海波,刘成龙,等.体素内不相干运动-弥散加权成像评价不同栓塞材料经动脉化疗栓塞治疗肝细胞癌效果及预后[J].介入放射学杂志,2024,33(02):140.
　GUAN Qinglong,CHNE Haibo,LIU Chenglong,et al.The application of IVIM-DWI in evaluating the efficacy and prognosis of TACE using different embolization materials for hepatocellular carcinoma[J].journal interventional radiology,2024,33(08):140.
[19]隰子涵,杨永波,邵国良.MRI和临床危险因素对中晚期肝细胞癌首次D-TACE近期疗效预测价值分析[J].介入放射学杂志,2024,33(04):376.
　XI Zihan,YANG Yongbo,SHAO Guoliang..The value of MRI and clinical risk factors in predicting the short-term efficacy of initial D-TACE in patients with intermediate and advanced stage hepatocellular carcinoma[J].journal interventional radiology,2024,33(08):376.

备注/Memo

备注/Memo:
（收稿日期：2020- 05- 18）
（本文编辑：边 佶）
更新日期/Last Update: 2020-08-16